KRYS News and Press, Krystal Biotech Inc. From 06/24/19

Minerva Neurosciences (NASDAQ: NERV ) +58%  on positive results from a Phase 2b clinical trial,  ISM2005 , evaluating seltorexant (MIN-202) in patients with insomnia disorder. More news on: Minerva Neurosciences, Inc., PCM, Inc., Krystal Biotech, Inc., Stocks on the move, ...

Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in Phase 2 trial was 2...

KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis KB105 is the second pipeline product based on the STAR-D platform and is part of a growing pipeline of gene therapy candid...

The following slide deck was published by Krystal Biotech, Inc. in conjunction with this Read more ...

PITTSBURGH, May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at ...

Krystal Biotech (NASDAQ: KRYS ): Q1 GAAP EPS of -$0.29  beats by $0.04 . More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

EMA grants PRIME eligibility for KB103 (bercolagene telserpavec)  to treat dystrophic epidermolysis bullosa Krystal Biotech announces five presentations of clinical and preclinical data at the Society for Investigative Dermatology (“SID”) Annual Meeting PITTSBURGH...

Krystal Biotech (KRYS) - The company announced presentations of clinical data for KB103 to treat DEB (dystrophic epidermolysis bullosa) and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome at t...

PITTSBURGH, April 29, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and precli...

The Company Krystal Biotech Inc. ( KRYS ) is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017 . It develops novel, "off-the-shelf", topical gene therapies for serious genetic skin diseases. Based on the strength ...